NCT02272998: Ponatinib for Patients Whose Advanced Solid Tumor Cancer Has Activating Mutations Involving the Following Genes: FGFR1, FGFR2, FGFR3, FGFR4, RET, KIT.

NCT02272998
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER++, PR+
Other Mutations: FGFR, KIT, PDGFR, FLT
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Ph+ase 2
Drug Category: Tyrosine-Kinase Inhibitor

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Senior)
Location of Metastases: 
Additional Notes: Must have FGFR, c-Kit, PDGFR-alpha, or FLT-3 mutation
Exclusions: Patients with symptomatic or progressive brain metastases are ineligible
https://ClinicalTrials.gov/show/NCT02272998

Comments are closed.

Up ↑